These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20044054)

  • 1. The role of emerging manufacturers in access to innovative vaccines of public health importance.
    Milstien JB; Kaddar M
    Vaccine; 2010 Feb; 28(9):2115-21. PubMed ID: 20044054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vaccines: producers in countries of the Southern hemisphere].
    Bertrand JJ
    Med Trop (Mars); 2007 Aug; 67(4):347-50. PubMed ID: 17926792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What are today's orphaned vaccines?
    Wilde H
    Clin Infect Dis; 2001 Sep; 33(5):648-50. PubMed ID: 11486287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimate of the global market for rifampicin-containing fixed-dose combination tablets.
    Norval PY; Blomberg B; Kitler ME; Dye C; Spinaci S
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S292-300; discussion S317-21. PubMed ID: 10593708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to vaccine technologies in developing countries: Brazil and India.
    Milstien JB; Gaulé P; Kaddar M
    Vaccine; 2007 Nov; 25(44):7610-9. PubMed ID: 17913312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology transfer in human vaccinology: a retrospective review on public sector contributions in a privatizing science field.
    Hendriks J
    Vaccine; 2012 Sep; 30(44):6230-40. PubMed ID: 22902679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GO License: only part of the solution.
    Batson A; Milstien JB
    Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States.
    Shen AK; Rodewald LE; Birkhead GS
    Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines as a global imperative--a business perspective.
    Stéphenne J
    Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all.
    Pagliusi S; Leite LC; Datla M; Makhoana M; Gao Y; Suhardono M; Jadhav S; Harshavardhan GV; Homma A
    Vaccine; 2013 Apr; 31 Suppl 2():B176-83. PubMed ID: 23598479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries.
    Batson A; Meheus F; Brooke S
    Vaccine; 2006 Aug; 24 Suppl 3():S3/219-25. PubMed ID: 16950010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public-private partnerships for health: their main targets, their diversity, and their future directions.
    Widdus R
    Bull World Health Organ; 2001; 79(8):713-20. PubMed ID: 11545327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paving the way for the introduction of new vaccines into developing countries.
    Chabalgoity JA
    Expert Rev Vaccines; 2005 Apr; 4(2):147-50. PubMed ID: 15889986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of globalization on vaccine development and availability.
    Milstien JB; Kaddar M; Kieny MP
    Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Children's Vaccine Initiative and vaccine supply: the role of the public sector.
    van Noort RB
    Vaccine; 1992; 10(13):909-10. PubMed ID: 1471410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine supply: a cross-national perspective.
    Danzon PM; Pereira NS; Tejwani SS
    Health Aff (Millwood); 2005; 24(3):706-17. PubMed ID: 15886165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health innovation networks to help developing countries address neglected diseases.
    Morel CM; Acharya T; Broun D; Dangi A; Elias C; Ganguly NK; Gardner CA; Gupta RK; Haycock J; Heher AD; Hotez PJ; Kettler HE; Keusch GT; Krattiger AF; Kreutz FT; Lall S; Lee K; Mahoney R; Martinez-Palomo A; Mashelkar RA; Matlin SA; Mzimba M; Oehler J; Ridley RG; Senanayake P; Singer P; Yun M
    Science; 2005 Jul; 309(5733):401-4. PubMed ID: 16020723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global public-private partnerships against neglected diseases: building governance structures for effective outcomes.
    Buckup S
    Health Econ Policy Law; 2008 Jan; 3(Pt 1):31-50. PubMed ID: 18634631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.